Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects in Patients With Diabetes Mellitus and Pre-diabetes and Heart Failure (SUGAR-DM-HF)
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 27 Nov 2019
Price : $35 *
At a glance
- Drugs Empagliflozin (Primary)
- Indications Heart failure; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms SUGAR-DM-HF
- 22 Nov 2019 Planned End Date changed from 28 Feb 2020 to 28 Aug 2020.
- 22 Nov 2019 Planned primary completion date changed from 28 Feb 2020 to 28 Aug 2020.
- 22 Nov 2019 Status changed from recruiting to active, no longer recruiting.